Ally Bridge Group Leads $150M Investment In Sorrento Therapeutics

Login to View

Ally Bridge Group, a Hong Kong-based healthcare private equity firm, has agreed to lead a US$150 million investment in NASDAQ-listed Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other diseases.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in